Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Determinants of Chronic Inflammatory Skin Disease Trajectories

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.

Who May Be Eligible (Plain English)

Who May Qualify: - dermatologist-diagnosed inflammatory skin disease - willing to sign a consent form Who Should NOT Join This Trial: - subject and/or the legal guardians are not able to give written willing to sign a consent form - pregnant and breastfeeding women - concurrent participation in a clinical trial - use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months - treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * dermatologist-diagnosed inflammatory skin disease * informed consent Exclusion Criteria: * subject and/or the legal guardians are not able to give written informed consent * pregnant and breastfeeding women * concurrent participation in a clinical trial * use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months * treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection

Treatments Being Tested

DRUG

Topical and systemic drugs

Recruitment and follow-up will be independent on the type of treatment

Locations (1)

Department of Dermatology and Allergy, University Hospital Schleswig-Holstein
Kiel, Germany